HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Bolt Biotherapeutics (NASDAQ:BOLT) and maintained an $8 price target.
August 08, 2023 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Bolt Biotherapeutics and maintained an $8 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Bolt Biotherapeutics. The maintained price target of $8 also indicates the firm's continued confidence in the company's potential. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100